The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Peptide drug developer Affymax (Palo Alto, CA, USA), which in 2006 clinched a global agreement with Takeda Pharmaceuticals (Tokyo) for the development and commercialization of its lead product ...

So, if you look at the yearly free cash flow of the 10 largest pharmaceutical companies, this is a lot of dry powder for acquisitions. The term “top” is rather subjective, as is here a mix of existing ...

Instead, we used a more subjective (but more relevant) mix ... products in 9 different therapeutic areas. 10 products are in phase III clinical trials, 9 in phase II, and 21 in phase I. The Q4 2022 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Vertex Pharmaceuticals Inc. (NASDAQ ... itself as a dominant player in the CF treatment market, with a strong product lineup that continues to drive revenue growth. The company's focus on ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat the roughly 5,000 CF patients who can't benefit from Vertex's other CF products. The other is from a phase ...